For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Tafamidis and Attruby represents a true breakthrough . These novel therapies stabilize the transthyretin protein, preventing its destructive build-up and lessening the burden of the con